Gemcitabine HCl Market Outlook Shaped by Growing Oncology Treatment Demand Gemcitabine HCl interferes with the synthesis of DNA and RNA in rapidly dividing cells, thereby slowing or stopping the growth of cancer cells. It is used either as a standalone therapy or in combination with other anticancer medicines. The drug has applications in the treatment of pancreatic, breast, ovarian, lung, and bladder cancers, among others. The broad therapeutic use of gemcitabine continues to support its demand across hospitals, specialty clinics, and oncology centers. Request the Sample Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=67622